T-Therapeutics raised a $133 million oversubscribed Series B to advance two TCR-TCR engager programs into clinical proof-of-concept. The UK-based company’s OpTiMus platform uses a repertoire of fully human TCRs to pursue selectively targeted intracellular antigens considered difficult to drug. The oncology program targets solid tumors, while the immunology program aims to selectively deplete pathogenic immune cells driving chronic inflammation. The syndicate included new and returning investors such as Advent Life Sciences and the British Business Bank, along with major strategics including Johnson & Johnson Innovation, Eli Lilly, and others. The financing highlights continuing investor appetite for next-generation T cell engager modalities, particularly where platform claims include improved specificity and a path to differentiation in solid tumor and autoimmune settings.